Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

[Chronic HBV and HDV infection]

GIE 2020: a clear vision for our future.

Cytokines and Chemokines in HBV Infection

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

HBV life cycle and novel drug targets

Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

Towards curative therapy of chronic viral hepatitis

HBV Infection and Chronic Hepatitis B

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection

[The dental care and treatment of periodontal disease in mental deficient adults. II. A method and effect of oral hygiene instruction (author's transl)].

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

Clinical Practice Guidelines EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

Risk of hepatocellular carcinoma in hepatitis B and D virus co‐infected patients: A systematic review and meta‐analysis of longitudinal studies

Hepatitis Delta Virus: Epidemiology, Natural Course and Treatment

Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside

Entry Inhibitors of Hepatitis B and D Viruses.

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure

Diagnostic ability of optical coherence tomography with a normative database to detect band atrophy of the optic nerve.

Epidemiology and Natural History of Chronic Hepatitis B Virus Infection

[Multivariate analysis of acute leukemia].

Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium